Immunoblotting analysis revealed that JN-KI3 would effectively inhibit PI3K/AKT signaling with concentration- and time-dependent manners in hematologic cancer cells even at a low concentration. This evidence concerns the gene ERMN and hematopoietic and lymphoid cell neoplasm.